Global Healthcare Currency Hedged ETF
About this ETF
DRUG aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars.
Scout Score
An independent score calculated by ETF Scout across 7 real-data factors (cost, diversification, tracking, liquidity, fund strength, performance, income), ranked against other funds in the same category.
Strengths
No standout strengths relative to category peers.
Weaknesses
- Wider index tracking — 14.15% tracking error, looser than 86% of International Shares peers.
- Weak long-term return — +8.3% p.a. (blended), trails 86% of rated International Shares peers.
- Concentrated holdings — top holdings make up 52.2% of the fund, more concentrated than 84% of International Shares peers.
Performance (as of 5 Nov 2026)
Total returns, net of fees. Periods longer than 1 year are annualised.
Price history
Cumulative return over the selected period, indexed to 0% at the start of the range.
Geographic exposure (as at 4 Nov 2026)
Country (where the company is based).
United States
Switzerland
United Kingdom
Japan
Denmark
France
Germany
China
Netherlands
Belgium
Brazil
MalaysiaSector breakdown (as at 4 Nov 2026)
How your portfolio's holdings are spread across GICS sectors.
Top holdings (as of 4 Nov 2026)
The fund's largest individual holdings, ranked by portfolio weight.
- 1.
Eli Lilly & Co8.92%
- 2.
Johnson & Johnson7.56%
- 3.
Abbvie Inc6.84%
- 4.
Merck & Co Inc4.87%
- 5.
Unitedhealth Group Inc4.83%
- 6.
Astrazeneca plc4.23%
- 7.
Roche Holding AG4.04%
- 8.
Novartis AG3.92%
- 9.
Thermo Fisher Scientific Inc3.73%
- 10.
Amgen Inc3.26%
- 11.
Gilead Sciences Inc2.93%
- 12.
Abbott Laboratories2.70%
- 13.
Pfizer Inc2.37%
- 14.
Intuitive Surgical Inc2.30%
- 15.
Danaher Corp2.23%
- 16.
Novo Nordisk A/S2.12%
- 17.
Medtronic plc1.82%
- 18.
Stryker Corp1.78%
- 19.
Bristol-Myers Squibb Co1.77%
- 20.
Vertex Pharmaceuticals Inc1.50%